No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages 371-375

  Ericson, Jessica E ^a,b   Thaden, Joshua ^a   Cross, Heather R ^b   Clark, Reese H ^c   Fowler, Vance G ^a,b   Benjamin, Daniel K ^a,b   Cohen Wolkowiez, Michael ^a,b   Hornik, Christoph P ^a,b   Smith, P Brian ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c Pediatrix Obstetrix Center for Research and Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; GENTAMICIN; OXACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT; COAGULASE;

ANTIBIOTIC THERAPY; ARTICLE; BIRTH WEIGHT; BLOODSTREAM INFECTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; DELAYED VANCOMYCIN THERAPY; DISEASE DURATION; EMPIRICAL VANCOMYCIN THERAPY; FEMALE; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; INFANT; INFANT DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN INTENSIVE CARE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMALL FOR DATE INFANT; VERY LOW BIRTH WEIGHT; BACTEREMIA; DRUG EFFECTS; ENZYMOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MORTALITY; NEONATAL INTENSIVE CARE UNIT; NEWBORN; SECONDARY PREVENTION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; SURVIVAL ANALYSIS; TIME FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COAGULASE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; SECONDARY PREVENTION; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84937559333     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000573     Document Type: Article

References (33)

1. Boghossian NS, Page GP, Bell EF, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. J Pediatr. 2013;162:1120-1124.
2. Ascher SB, Smith PB, Clark RH, et al. Sepsis in young infants with congenital heart disease. Early Hum Dev. 2012;88 (suppl 2):S92-S97.
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2, pt 1):285-291.
4. Mularoni A, Madrid M, Azpeitia A, et al. The role of coagulase-negative staphylococci in early onset sepsis in a large European cohort of very low birth weight infants. Pediatr Infect Dis J. 2014;33:e121-e125.
5. Liljedahl M, Bodin L, Schollin J. Coagulase-negative staphylococcal sepsis as a predictor of bronchopulmonary dysplasia. Acta Paediatr. 2004;93:211-215.
6. Stoll BJ, Hansen NI, Adams-Chapman I, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birthweight infants with neonatal infection. JAMA. 2004;292:2357-2365.
7. Payne NR, Carpenter JH, Badger GJ, et al. Marginal increase in cost and excess length of stay associated with nosocomial bloodstream infections in surviving very low birth weight infants. Pediatrics. 2004;114:348-355.
8. Freeman J, Epstein MF, Smith NE, et al. Extra hospital stay and antibiotic usage with nosocomial coagulase-negative staphylococcal bacteremia in two neonatal intensive care unit populations. Am J Dis Child. 1990;144:324-329.
9. Rubin LG, Sanchez PJ, Siegel J, et al.; Pediatric Prevention Network. Evaluation and treatment of neonates with suspected late-onset sepsis: A survey of neonatologists' practices. Pediatrics. 2002;110:e42.
10. Qu Y, Daley AJ, Istivan TS, et al. Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation. Ann Clin Microbiol Antimicrob. 2010;9:16.
11. Lawrence SL, Roth V, Slinger R, et al. Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: A retrospective cohort study. BMC Pediatr. 2005;5:49.
12. Ofek-Shlomai N, Benenson S, Ergaz Z, et al. Gastrointestinal colonization with ESBL-producing Klebsiella in preterm babies-is vancomycin to blame? Eur J Clin Microbiol Infect Dis. 2012;31:567-570.
13. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR. 1995;44(RR-12):1-13.
14. Spitzer AR, Ellsbury DL, Handler D, et al. The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system-Tools for 'meaningful use' in continuous quality improvement. Clin Perinatol. 2010;37:49-70.
15. Jean-Baptiste N, Benjamin DK Jr, Cohen-Wolkowiez M, et al. Coagulasenegative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol. 2011;32:679-686.
16. Olsen IE, Groveman SA, Lawson ML, et al. New intrauterine growth curves based on United States data. Pediatrics. 2010;125:e214-e224.
17. McKamy S, Hernandez E, Jahng M, et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158:422-426.
18. Vella-Brincat JW, Begg EJ, Robertshawe BJ, et al. Are gentamicin and/or vancomycin associated with ototoxicity in the neonate? A retrospective audit. Neonatology. 2011;100:186-193.
19. Robertson CM, Tyebkhan JM, Peliowski A, et al. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Acta Paediatr. 2006;95:214-223.
20. Iosifidis E, Evdoridou I, Agakidou E, et al. Vancomycin-resistant Enterococcus outbreak in a neonatal intensive care unit: epidemiology, molecular analysis and risk factors. Am J Infect Control. 2013;41:857-861.
21. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51:e38-e45.
22. Patel SJ, Oshodi A, Prasad P, et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J. 2009;28:1047-1051.
23. Clark RH, Bloom BT, Spitzer AR, et al. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117:1979-1987.
24. Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, et al. Antimicrobial use and the influence of inadequate empiric antimicrobial therapy on the outcomes of nosocomial bloodstream infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2004;25:735-741.
25. Benjamin DK, DeLong E, Cotten CM, et al. Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J Perinatol. 2004;24:175-180.
26. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988-1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106:1387-1390.
27. Chiu CH, Michelow IC, Cronin J, et al. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J. 2011;30:273-278.
28. Cotten CM, McDonald S, Stoll B, et al.; National Institute for Child Health and Human Development Neonatal Research Network. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118:717-722.
29. Cotten CM, Taylor S, Stoll B, et al.; NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123:58-66.
30. Clark RH, Bloom BT, Spitzer AR, et al. Empiric use of ampicillin and cefotaxime, compared with ampicillin and gentamicin, for neonates at risk for sepsis is associated with an increased risk of neonatal death. Pediatrics. 2006;117:67-74.
31. de Man P, Verhoeven BA, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355:973-978.
32. Tsai MH, Hsu JF, Chu SM, et al. Incidence, clinical characteristics and risk factors for adverse outcome in neonates with late-onset sepsis. Pediatr Infect Dis J. 2014;33:e7-e13.
33. Greenberg RG, Benjamin DK Jr, Gantz MG, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr. 2012;161:264-9.